Amifampridines (3,4 Diaminopyridine and 3,4 Diaminopyridine Phosphate): Drugs of Choice for Lambert-Eaton Myasthenic Syndrome

Amifampridines have been known to be effective as symptomatic treatment of Lambert-Eaton myasthenic syndrome since 1983. Food Drug Administration (FDA) approved amifampridines, the most studied safe and effective drugs in the neuromuscular diseases, are available for the general use for symptomatic treatment of LEMS, 60 years after the first description of LEMS and 40 years after the first trial of 3,4-DAP in LEMS.

[1]  J. Verschuuren,et al.  Lowering the cutoff value for increment increases the sensitivity for the diagnosis of Lambert‐Eaton myasthenic syndrome , 2020, Muscle & nerve.

[2]  Luay Shayya,et al.  Low specificity of voltage-gated calcium channel antibodies in Lambert–Eaton myasthenic syndrome: a call for caution , 2018, Journal of Neurology.

[3]  Shin J Oh.  Distinguishing Features of the Repetitive Nerve Stimulation Test Between Lambert–Eaton Myasthenic Syndrome and Myasthenia Gravis, 50-Year Reappraisal , 2017, Journal of clinical neuromuscular disease.

[4]  B. Lang,et al.  Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome , 2017, Neurology.

[5]  J. Verschuuren,et al.  Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Shin J Oh,et al.  Low‐dose guanidine and pyridostigmine: relatively safe and effective long‐term symptomatic therapy in Lambert‐Eaton myasthenic syndrome , 1997, Muscle & nerve.

[7]  P. Bain,et al.  Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome , 1996, Neurology.

[8]  P. O'Suilleabhain,et al.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. , 1995, The New England journal of medicine.

[9]  L. Gutmann,et al.  Trends in the association of Lambert‐Eaton myasthenic syndrome with carcinoma , 1992, Neurology.

[10]  C. Chalk,et al.  Response of the Lambert‐Eaton myasthenic syndrome to treatment of associated small‐cell lung carcinoma , 1990, Neurology.

[11]  I. Rosén,et al.  4-aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome. , 1977, Journal of neurology, neurosurgery, and psychiatry.